Aurinia Pharmaceuticals Inc (AUPH NASDAQ) stock market data APIs
$8.1891
-0.07(-0.9%)
as of April 25, 2025
Aurinia Pharmaceuticals Inc Financial Data Overview
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
8.1891
Open
8.1205
High
8.2325
Low
7.9113
52 wk Range
4.92-10.67
Market Cap
1 107 M
P/E Ratio
202.5
Shares Outstanding
137 M
Revenue
235 M
Beta
1.215
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 235 M
- EBITDA: 31 964 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?
Aurinia Pharmaceuticals (NASDAQ:AUPH) has had a rough three months with its share price down 10%. But if you pay close attention, you might find that its key financial indicators look quite decent, wh...
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March
We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stands against o...
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point
Even though Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are encourag...
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
The annual results for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were released last week, making it a good time to revisit its performance. It looks like a credible result overall - although revenues...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
